A game changer for chronic wounds, cancer, inflammatory diseases & beyond.

4-in-1 synthetic biology, cell and gene therapy platform

At Aurealis Therapeutics, we have built a unique multi-target cell and gene therapy platform to address unmet medical needs.

Discover the mode of action of our lead clinical asset AUP-16, a topical cell therapy that enables the healing of Diabetic Foot Ulcers (DFU) and other chronic, non-healing wounds.

Play Video

THE TEAM, THE SCIENCE & the outcome

Meet the TEAM

At Aurealis Therapeutics we are passionate about our science to make a difference for patients. Meet the Management Team, the Scientific Advisory Board, the Board of Directors, and the Aurealis Therapeutics Team Members.

Discover the SCIENCE

Our team takes pride in mastering the most advanced cell and gene therapy science, and making work in real life, from the lab to pre-clinical and to the clinic.

See the OUTCOME

Generating pre-clinical, clinical and health-economic evidence is how we want to make a difference. Seeing non-healing wounds healing, seeing how cancer deaths can be prevented – this is what matters the most.

Learn more About this
life-changing
technology

For Investors and Strategic Partners

Contact us

AUREALIS NEWS

Aurealis Therapeutics Strengthens Its Board of Directors by Appointing Jean de Gunzburg as a New Member

Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company creating bacteria-based multi-factor cell and gene therapies for chronic wounds and cancer, announced today that Jean de Gunzburg, Scientist and Investor, Founder and Chairman of Zagdanut Ltd, Director of Cardiawave SA, previously CSO and Director of Da Volterra, and Founder and Chairman of Metsya Ltd, has been […]

Read More

Aurealis Therapeutics Accelerates Oncology Program: First abstract published at ASCO as the team prepares for Annual Meeting in Chicago

Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for unmet medical needs, accelerates its expansion in Oncology with its first-in-class four-in-one Bacterial Cell and Gene Therapy AUP-55. The companyโ€™s first abstract, Effect of multi-targeting bacterial gene therapy on tumor regression and survival in mouse models of ovarian and intraperitoneal cancer, has […]

Read More

Aurealis Therapeutics announces approval of multi-center, randomized, placebo-controlled diabetic foot ulcer Phase 2 study to start May 2023 in Italy, Germany and Poland.

Aurealis Therapeutics, a Swiss-Finnish private clinical-stage synthetic biology company focusing on the development of lactic acid bacteria -based GMO cell and gene therapies, announces clinical trial application (CTA) approval of a multi-center, randomized, placebo-controlled diabetic foot ulcer (DFU) Phase 2 study to start this month in Italy, Germany, and Poland. The Global Coordinating Investigator of […]

Read More